Ibom Medical Journal (Dec 2020)

Rituximab-induced acute thrombocytopaenia in an African lupus patient: A case report

  • Akpabio AA,
  • Nga CN,
  • Udofia UK,
  • Asuka ES,
  • Orji PN

DOI
https://doi.org/10.61386/imj.v13i3.195
Journal volume & issue
Vol. 13, no. 3

Abstract

Read online

Drug-induced acute thrombocytopaenia (DITP) is a complication of various medications resulting in a platelet count <50 x 109/L from prior normal levels. It typically occurs within 1-2 weeks post-administration but can occur rapidly within 1-3 days with previous exposure. Rituximab (an anti-CD20 antibody) used to treat many autoimmune cytopaenias, has been reported to cause thrombocytopaenia mostly in lymphoma patients. Reports in lupus are rare possibly because of off-label use. We hereby highlight the case of a 39-year old African lady who developed acute thrombocytopenia 12 days post-rituximab. Frequent monitoring of blood counts will enhance identification and treatment of this complication.

Keywords